Bhuston... This comment made me spew my water all over my computer. Happy Good Friday all. Lets consider it Jesus's divine intervention that keeps your guarantee a 100% certainty. Lol.
OK. No it does not. It targets all HPV16 or HPV18 mediated diseases. There are over 100 HPV subtypes. There are many that cause high risk lesions. Of the 150-200 types of HPV known,15 are classified as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), 3 as probable high-risk (26, 53, and 66), and 12 as low-risk (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108).
Although there are that many high risk strains, ~ 70% of the high risk lesions are caused by HPV 16, and another 20% by HPV 18. The other ~10% are caused in the largest amount by 31 then 33, then 35, then 39, then down the line. The higher numbers are the newer strains.
Now there may be some immunologic overlap by INOs HPV vaccine targeting HPV 16 and 18 for other strains, but that has not been tested for.
To say it targets all HPV-caused disease is ignorant at best. I am sorry.
Still long and strong. Added more in the $2.50 range. Missed the dip in the 2.30s-2.20s.
Sentiment: Strong Buy
Yup. Some weak hands sold this morning with the lack of the 10K. Just as I thought. Looks like people are settling in now. My prediction for the short term: its gonna go up, down, or stay the same from here for a while. Like I said above, who gives a F---.
My prediction for the long term: This is going up. That's why I don't care. Its OTC. Penny flippers can make pennies by scaring some spec money. Its gonna be a rocky way up because of that. But people who know the science behind this (like me and infinitewisdumb and others) know what we have here. People who also look at the big picture as far as a business see:
-Business is expanding behind a newly appointed team of business people and scientists.
-They have the rights to a new molecule that has completed phase IIa trials with very positive results in multiple indications.
- They now have the funding to continue with those trials with eltoprazine
- They also have the funding to continue to progress with Lympro, and partner Lympro when it best suits AMBS rather the potential partner. They also have the option to go it alone if they deem the partnership is not in their best interest.
- Publication of MANF1 (Not CDNF or MANF2) role in diabetes and beta cell death by Dr. Saarma, confirming the previous work of Dr. Urano in Cell Reports, a top peer reviewed journal of Cell Press, the publisher of Cell.
- Patent for MANF1 gives all rights to AMBS Dec 2012.
Yes considerable dilution did happen. That's why we are not at 0.15 right now. So be it.
I don't know why all this talk about the 10-K. Who the F cares. What's gonna happen? They get put on notice by the OTC... Oh shet!!! They are trying to uplist to Nasdaq anyway. You guys are a bunch of pansies (not you tanis). Just relax. They didn't hire a new army of workers to actually get less work done.
There will be nothing of significance in a 10-K about last year's events. Yes we will find out about how much dilution happened. Yes it will scare some of the weaker hands.
But there are still good things to come this year.
It depends on the technology the blood test uses, and how complicated the output is.
Since I am a dermatopathologist, I can give you some of the business side of this.
This test uses fairly simple technology:
So costs for this test:
1) PBMC isolation from whole blood using Ficoll density gradient centrifugation for separation
2) Counting the cells on a hemacytometer
3) Plating a set number of these cells in a 96-well multiplate
4) Culturing them with media (RPMI + either fetal bovine serum or normal human serum+ antibiotics, likely in triplicate to quadruplicate per condition) with and without pokeweed mitogen for 24-48 hours
5) Staining and running a panel of cell surface antibodies to detect markers on the surface of T cells and B cells
So, to run a panel of markers on whole blood by flow cytometry from patients to detect lymphomas/leukemia (clonality), or to examine CD4 count in HIV+ patients usually costs ~$250-400, depending on the lab.
This test is significantly more complicated than simply running whole blood on a flow cytometer, requires culture/stimulation of cells, then a stimulation index.
If I was running the lab (I don't run a clinical lab as I am part of anatomic pathology, so this is a best guestimate), a reasonable charge for this test would be about $400-500. I could easily see a charge of $500-600, and that would be totally reasonable for medicare and private insurances, and they would easily pay that much for that test.
Its on hold due to funding. Did not complete the trial.
Of note INO has a Syncon vaccine for WT1 mutated tumors that is in preclinical development. INO will not push Southamptoms vaccine, because they have a better one they will try out in the future.
OK, go to Google. Type in Hermo Pharma. That is Saarma's company that he cofounded in 2008. Go to pipeline. look for any mention of MANF. It is not there. Because they lost. They have CDNF, which is MANF2. That is in preclinical for Parkinson's.
Or type in Hermo Pharma and MANF on Google. It will change it to Hermo Pharma and Manuf. Click on the did you mean MANF? Then 40 hits will pop up. Most are publications. There is a slide set that says CDNT is better than MANF without showing any data. Hmmm... If they have any rights to MANF, would they be bashing it on their slideset (without showing data)? Probably would only do that if they are competing with MANF, right?
Where did a concern come from though? This is old news. We have known since 2012 that AMBS owns the rights to MANF. Is it because Saarma published a paper confirming the role of MANF in diabetes? Is that why the share price dropped on Friday? Because someone was questioning MANF rights?
You realize MANF does not = MANF2. But MANF2 = CDNF. Completely different protein. Its like saying who knows what Monday will bring for Amarantus because Amgen owns the rights to Erythropoietin (Epogen). You are just dumb. I am sorry.
Good call on one of the biggest down day of biotechs, especially spec ones. Can you find more than 10 that are up today out of the 400 or so?
Your call is uncanny. You should be one of the X-Men.
No its for CIN 2/3. The quoted rate of regression in CIN I is ~58% (it says it above). The rate of regression of CIN2/3 is 28% in those patients tested in the study above. Its a free manuscript. Open access to all. Read it. I did. That is why I said what I did and gave you the way to find it for yourself (since I can't post links on yahoo).
If you question someone else's DD, at least do that person's DD before questioning it as if it is wrong.
HPV16, 18, 31, and 33 are all oncogenic HPVs with very similar (~98-99% sequence homology) of E6 and E7 proteins.
Where did you do your research?
Type this in your search browser:
Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA Phenotype
An article in Clinical Cancer Research should come up.
Here's an excerpt:
"Persistent infection with a high risk, or oncogenic type of human papillomavirus (HPV) is necessary but not sufficient for the development of most squamous carcinomas of the cervix and their precursor lesions, cervical intraepithelial neoplasia (CIN; ref. 1). CIN1, CIN2, and CIN3 lesions represent a spectrum of disease. Low-grade, or CIN1 lesions, represent a chronic HPV infection, in which HPV DNA is episomal and intact virion production and shedding occur. In women who are immunocompetent, many low-grade, or CIN1 lesions, will nonetheless eventually regress without intervention (1, 2). Reported rates of regression range up to 58% over 24 months (3). A very small percentage (∼2%) will progress to high-grade lesions.
Experimental Design: Our study cohort included healthy women with high-grade cervical lesions (CIN2/3) with residual visible lesions after colposcopically directed biopsy. We prospectively followed 100 women over 15 weeks before standard resection. HPV typing was done using PCR and a reverse line blot detection method.
Results: The rate of spontaneous histologic regression, defined as (CIN1 or less at resection) was 28%."
Generally, think of it as 1/3 of high risk lesions per year progress, 1/3 stay the same, and 1/3 regress. The longer it does not go away, the longer the likelihood of progression to cancer or from CIN2 to CIN3.
And there would be no way to know who got the study drug in a blinded trial, especially one where ~1/3 of the lesions get better on their own without treatment.
March 10th, percentage of volume short was 50% of shares. Since then it has bounced around from 20-40%, but the overall trend has been gradual decline. Yesterday, 24% of the shares (1.4 million) were sold short.
It posts it next to your post (for only you to see) in case you have second thoughts about your post and want to remove it from the board. Imagine it saying (only to you):
Remove? If you like the post, you can leave it. If you don't like it, it gives you the option to remove it. Like if you post your telephone number accidentally.
How IDRA, INO, CPRX, NWBO, GALE, ARIA and others don't just get a lawyer to sue "The Street" for libel/slander and a private investigator to look into the financials of AF, JC, and anyone heavily invested in "The Street" at around the times when their persistent and perpetual bashing of a company begins is beyond me.
They are on their own deadline for releasing data. They will do it when it is best for the company and shareholders, including me and Lincoln Park and Dominion. I could give a f*$k about penny flippers and if they lose money. Number one rule of investing is patience. I am learning. Should they release news when it would cause a 10% bump in price so penny flippers can make $500? Is that best for their company? Or is it best to wait until all their ducks are in a row?
The key is to increase value for investors.
The manipulation is due to being on the OTC where manipulators have free reigns to destroy a stock.
GCs and AMBSs main goal should be to get out of the OTC as quickly as possible. And if that can happen by holding data for a week, or a month, or two months. Then so be it.
Look at INO. Look at IDRA. Look at ELTP.
Do you think maybe Lincoln Park or one of the other investors didn't tell him: OK, we gave you the funding you needed to be a company (20+ million or 2 million if you think Dominion), now wait until we tell you to release the great data you just showed us.
Lets get the penny flippers out. Real investors in. I am all for it.
I have been buying 2000 to 20000 shares every other day or so as the price drops to 0.077-0.082. Not worried in the slightest.